Determinazione nr. 2209 del 12/07/2023
NULLAOSTA ALL’AVVIO DELLA SPERIMENTAZIONE DENOMINATA DZ2022E0005 “A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTI-CENTER STUDY OF DZD9008 VERSUS PLATINUM-BASED DOUBLET CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATION” DA EFFETTUARSI PRESSO L’U.O. ONCOLOGIA DI RAVENNA E CONTESTUALE APPROVAZIONE DELLA CONVENZIONE PER SPERIMENTAZIONE CLINICA.
Pdf
Stampa
Provvedimento
12-07-2023
Determinazione nr. 2209 del 12/07/2023
NULLAOSTA ALL’AVVIO DELLA SPERIMENTAZIONE DENOMINATA DZ2022E0005 “A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTI-CENTER STUDY OF DZD9008 VERSUS PLATINUM-BASED DOUBLET CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATION” DA EFFETTUARSI PRESSO L’U.O. ONCOLOGIA DI RAVENNA E CONTESTUALE APPROVAZIONE DELLA CONVENZIONE PER SPERIMENTAZIONE CLINICA.
NULLAOSTA ALL’AVVIO DELLA SPERIMENTAZIONE DENOMINATA DZ2022E0005 “A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTI-CENTER STUDY OF DZD9008 VERSUS PLATINUM-BASED DOUBLET CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMAL
nessuna
12-07-2023